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Coronary artery disease, in the development of which inflammation mediated by innate 
immune cells plays a critical role, is one of the leading causes of death worldwide. 
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are a widely 
used lipid-lowering drug that has lipid-independent vasculoprotective effects, such as 
improvement of endothelial dysfunction, antioxidant properties, and inhibitory effects on 
inflammation. Despite recent advances in lipid-lowering therapy, clinical trials of statins 
suggest that anti-inflammatory therapy beyond lipid-lowering therapy is indispensible to 
further reduce cardiovascular events. One possible therapeutic option to the residual risk 
is to directly intervene in the inflammatory process by utilizing a nanotechnology-based 
drug delivery system (nano-DDS). Various nano-sized materials are currently developed 
as DDS, including micelles, liposomes, polymeric nanoparticles, dendrimers, carbon 
nanotubes, and metallic nanoparticles. The application of nano-DDS to coronary artery 
disease is a feasible strategy since the inflammatory milieu enhances incorporation of 
nano-sized materials into mononuclear phagocytic system and permeability of target 
lesions, which confers nano-DDS on “passive-targeting” property. Recently, we have 
developed a polymeric nanoparticle-incorporating statin to maximize its anti-inflammatory 
property. This statin nanoparticle has been tested in various disease models, including 
plaque destabilization and rupture, myocardial ischemia-reperfusion injury, and ventricu-
lar remodeling after acute myocardial infarction, and its clinical application is in progress. 
In this review, we present current development of DDS and future perspective on the 
application of anti-inflammatory nanomedicine to treat life-threatening cardiovascular 
diseases.
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ANTi-iNFLAMMATORY THeRAPeUTiCS FOR CORONARY 
ARTeRY DiSeASe
Coronary artery disease is the leading cause of death worldwide and can be life threatening especially 
when it develops into acute myocardial infarction (AMI), the most severe type of atherosclerotic 
cardiovascular disease. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors (statins) are potent inhibitors of cholesterol synthesis and established therapies for the 
TAbLe 1 | Characteristics of various nano-sized materials as drug delivery systems.
Micelle Liposome Polymer nanoparticle Dendrimer Carbon nanotube Metallic nanoparticle
Geometry Spherical vesicles 
composed of 
a monolayer of 
lipids or synthetic 
amphiphiles
Spherical vesicles 
composed of 
phospholipids bilayers
An assembly of 
macromolecular 
polymers
Highly branched 
monodisperse 
macromolecules 
from a central core
Single or multi-walled tubular 
form of graphite sheets
A magnetic core coated 
with hydrophilic polymers
Size (nm) 10–100 40–1,000 20–1,000 3–20 0.5–3.0 × 20–1,000 60–150 (core 4–5)
Features Encapsulation of 
hydrophobic agents 
inside
Encapsulation of 
hydrophilic agents inside, 
embedding hydrophobic 
agents in the membrane
Incorporation of 
hydrophilic and 
hydrophobic agents, 
controlled release of 
incorporated agents
Multivalent 
properties by 
exterior funciton 
groups
Encapsulation of agents 
into its inner space with 
chemically modified external 
surface
Contrast agents for 
biological imaging, 
photothermal properties
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prevention of coronary artery disease. The first randomized 
trial to demonstrate that cholesterol-lowering therapy with 
statins improves prognosis in patients with high cholesterol and 
coronary artery disease, the Scandinavian Simvastatin Survival 
Study (4S), was reported in 1994 (1). Since then, lipid-lowering 
therapy with statins has become the mainstay for the prevention 
of coronary artery disease. The subsequent studies for the sec-
ondary prevention such as the CARE (Cholesterol and Recurrent 
Events) (2) and LIPID (Long Term Intervention with Pravastatin 
in Ischemic Disease) trials (3) further extended that the benefits 
of statins to the majority of patients whose cholesterol levels 
were in the normal range. The WOSCOPS (West of Scotland 
Coronary Prevention Study) (4) and the AFCAPS/TexCAPS 
(Air Force/Texas Coronary Atherosclerosis Prevention Study) 
(5) also extended the benefits for the primary prevention of 
atherosclerotic cardiovascular diseases. A decade after 4S, Ridker 
et al. demonstrated in the JUPITER (Justification for the Use of 
Statins in Primary Prevention: an Intervention Trial Evaluating 
Rosuvastatin) trial that high-intensity cholesterol-lowering ther-
apy with statins reduced high-sensitivity C-reactive protein levels 
to lower than 2 mg/L and then achieved further risk reduction 
of cardiovascular events even among patients with normal cho-
lesterol levels (6). Statins have a wide range of lipid-independent 
cardiovascular protective effects (so called “pleiotropic effects”), 
such as improvement of endothelial dysfunction, antioxidant 
properties, and inhibitory effects on inflammation (7) This land-
mark study suggested that anti-inflammatory therapy beyond 
lipid-lowering therapy is needed to further reduce cardiovascular 
events. At present, plaque erosion appears on the rise as a cause of 
acute coronary syndrome (ACS) in this statin era (8), but plaque 
rupture of unstable plaques with macrophage accumulation, 
fibrous cap thinning, and lipid deposition, followed by arterial 
occlusive thrombosis remains the primary mechanisms of 
ACS. Despite recent advances in lipid-lowering therapy by the 
emergence of Niemann-Pick C1-Like 1 inhibitor (ezetimibe) 
(9, 10) and proprotein convertase subtilisin/kexin type 9 inhibi-
tors (11), there are still residual risks of cardiovascular events. 
One possible approach to the residual risks is to directly inter-
vene in the inflammatory process during atherogenesis. Current 
medicinal therapy, including statins, has limitation of bioavail-
ability in the diseased organs. Most small molecule drugs are 
absorbed from the intestines, metabolized in the liver, delivered 
to the bloodstream, and excreted from the kidneys, that is, drugs 
need to overcome the physiological barriers to achieve effective 
concentration in the blood and tissue. Adverse effects that any 
drugs possess may also limit their maximum dose in terms of 
safety. Recent innovation in nanomedicine can achieve effective 
drug delivery to targeted organs and cells, and spare undesirable 
adverse effects. In the first part of this review, we summarize 
recent advances in nanotechnology-based drug delivery system 
(nano-DDS). In the second part, we demonstrate the data of 
nano-DDS of statins in coronary artery disease for maximizing 
its anti-inflammatory effects.
vARiOUS NANO-SiZeD MATeRiALS  
AS DRUG DeLiveRY SYSTeMS
Currently, various nano-sized materials (nanomaterials) have 
been tested and approved in clinical settings: lipid nanoparticles 
such as micelles or liposomes (12), polymeric nanoparticles (13), 
dendrimers (14), carbon nanotubes, and metallic nanoparticles. 
The characteristics of these materials and clinical applications are 
as follows (Table 1).
Micelles
Micelles consist of lipids and other amphiphilic artificial mol-
ecules, such as polymers. Micelles are self-assembling in aqueous 
solution to form a monolayer with a hydrophobic phase inside so 
that they can incorporate hydrophobic therapeutic agents. The 
diameter of micelles is usually 10–100 nm and the enclosed space 
is more confined than that of liposomes.
Liposomes
Since United States Food and Drug Administration (FDA) approved 
liposomal formulations of doxorubicin and amphotericin B 
in the mid-1990s (15), liposomes have been investigated most 
extensively in nanomedicine with approval due to less toxicity for 
in vivo application and capacity to deliver a variety of payloads. 
Liposomes mainly consist of phospholipids to form bilayers with 
an aqueous phase inside, which confer superior biocompatibility 
on liposomes. They can not only incorporate hydrophilic thera-
peutic agents inside but also hydrophobic agents in the liposomal 
membrane. Macromolecular drugs, including nucleic acid 
and crystalline metals, can be also incorporated in liposomes. 
3Katsuki et al. Nanomedicine for Cardiovascular Disease
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The diameter of liposomes is usually 40–1,000  nm. Liposomes 
obtain specific characteristics through modification of its surface 
with polymers, antibodies, and protein. PEGylated liposomal 
doxorubicin (Doxil®) is the first FDA-approved nanomedicine 
and enhanced the drug concentration in malignant effusions by 
4-fold to 16-fold, while reducing cardiotoxic side effects (16).
Polymeric Nanoparticle
Food and Drug Administration-approved polymers, polylactic 
acid (PLA), polyglycolic acid (PGA), and poly lactic-co-glycolic 
acid (PLGA), are widely used for the synthesis of polymeric 
biodegradable nano-DDS, because they are eliminated from 
the body in the form of water and carbon dioxide. PLGA is a 
copolymer of PLA and PGA, the most frequently used constitu-
tion among these polymers, and is being tested for a DDS for 
intractable diseases, including cardiovascular disease. PLA is 
more hydrophobic, whereas PGA is more hydrophilic; the deg-
radation speed of PLGA can be adjusted by the PLA:PGA ratio 
and their molecular weights, which achieves controlled release 
of incorporated drugs. PLGA polymers incorporate hydrophilic 
and hydrophobic therapeutic agents, including chemicals 
and nucleotides by emulsion solvent diffusion methods. The 
diameter of polymeric nanoparticles widely ranges from 20 to 
1,000  nm. FDA-approved PLGA nanoparticle utilizing these 
advantages is leuprolide acetate (a testosterone inhibitor)-
incorporated nanoparticle for prostate cancer (Eligard®). PLGA 
achieves slow and sustained leuprolide acetate release after 
subcutaneous injection.
Dendrimer
Dendrimers are dendritically expanded macromolecules with 
monodisperse structure that consist of a central core, branch-
ing interior, and exterior functional groups (14). Dendrimers 
can incorporate therapeutic agents in their three-dimensional 
branching interior voids and work as a drug delivery carrier. 
The number of repeating branching cycles is called generations. 
Exterior function groups increase exponentially as generation 
increases, which confer multivalent properties on dendrim-
ers. This multivalent effect has the advantage of enhancing the 
binding capacity when its exterior surface is modified with some 
ligands or antibodies as an active targeting (17).
Carbon Nanotube
Carbon nanotubes are a subfamily of fullerenes and consist of 
graphite sheets rolled up into tubular form. As drug carriers, they 
can incorporate drugs into its inner space and have a chemically 
modified external surface with biomolecules, such as proteins 
and nucleotides, for selective targeting. Carbon nanotube-based 
anticancer therapy such as cisplatin-incorporated carbon nano-
horn is currently being investigated (18).
Metallic Nanoparticle
Metallic nanoparticles include iron oxide and gold nano-
particles. Iron oxide nanoparticles consist of a magnetic 
core (4–5  nm) and hydrophilic polymers such as dextran 
or poly(ethyleneglycol)s. Superparamagnetic iron oxide 
(SPIO) (60–150  nm) has been investigated as a contrast 
agent for magnetic resonance imaging (MRI). Ferumoxytol 
(Feraheme®), caraboxymethydextran-coated iron oxide, is the 
only FDA-approved SPIO. The clinical use of ferumoxytol is 
limited to iron replacement therapy for patients with chronic 
kidney disease and is under investigation as an imaging agent. 
Resovist®, carboxydextran-coated iron oxide, has been with-
drawn from FDA-approved drugs due to lack of clinical users, 
and is currently available in limited countries including Japan 
(19). Gold nanoparticles has unique photothermal properties, 
tunable size and shape, and easily modified surface. No gold 
nanoparticles have been clinically approved to date, but they 
are actively investigated especially in research fields targeting 
cancer (20).
Although micro-sized particles are considered to be biologi-
cally inert, nano-sized materials could activate innate immune 
sensors. In fact, nano-sized inorganic metal oxides, such as 
silica dioxide (SiO2) and titanium dioxide (TiO2) (21), and silver 
nanoparticle (22) have been reported to activate the NLR pyrin 
domain containing 3 (NLRP3) inflammasome in human mac-
rophages. Since carbon nanotubes are fiber-shaped material, the 
morphology of which is similar to that of asbestos, the concern 
for the toxicity of carbon nanotubes has been raised (23). In 
animal models, intratracheal exposure with the above-mentioned 
nanomaterials demonstrated airway inflammation (21, 24). The 
activation of inflammasome is mediated by potassium efflux (25), 
lysosome degradation that results in cathepsin B leakage, gen-
eration of reactive oxygen species (ROS) (26), and production of 
adenosine (27). These data suggested that greater caution might 
be needed to these widely produced nanomaterials.
IN VIVO KiNeTiCS OF NANOPARTiCLe-
MeDiATeD DRUG DeLiveRY SYSTeM
Although there are numerous determinants to affect in vivo kinet-
ics of nano-DDS other than geometry as previously discussed, 
the size and surface modification of nanoparticles are the most 
important in the physiological behaviors of nano-DDS. Large-
sized nanomaterials (>1,000 nm in diameter) tend to accumu-
late in the liver and lungs, and sometimes can be the cause of 
microemboli in capillaries, while small-sized nanomaterials 
(<10  nm) tend to be excreted from the kidneys. Middle-sized 
nanomaterials (10–1,000  nm) remain in circulation for longer 
time avoiding renal excretion. These circulating nanomaterials 
are generally incorporated by the mononuclear phagocytic sys-
tem (MPS) in the liver, spleen, lymph nodes, and bone marrow 
(28). A surface modification with polyethylene glycol (PEG) 
serves as a hydrophilic shield that reduces protein absorption 
and undesirable non-specific interaction with MPS, which is 
preferable for nano-DDS in cancer. However, incorporation of 
nanomaterials into MPS itself is one of the intended mechanisms 
of drug delivery, especially when targeting inflammatory diseases 
including atherosclerosis. On the other hand, accumulation of 
nanomaterials depends on the permeability of target lesions. 
In tumor blood vessels, inflammatory atherosclerotic lesions, and 
ischemic myocardium, nanomaterials extravasate from blood 
vessels due to enhanced permeability. Tumors lack functional 
lymphatic vessels in their tumor microenvironment, which 
FiGURe 1 | Schematic description of determinants of physiological behavior of nanomaterials. (Upper panel) Nanomaterial-side determinants: geometry, size, and 
surface modification. (Lower panel) Vasculature-side determinants induced by inflammation: enhanced uptake of nanomaterials by inflammatory cells and enhanced 
vascular permeability and retention (EPR) effect.
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enhances the accumulation of nanomaterials. These phenomena 
are referred to as “enhanced permeability and retention effects” 
(29) or “passive-targeting” (Figure 1).
By contrast, “active-targeting” strategy employs target-specific 
structures, such as antibodies and proteins on nanomaterials, 
which bind to the target molecule that is specific for a certain 
disease process. “Active-targeting” strategy is being developed 
in cancer therapeutics targeting molecules associated with 
angiogenesis and cell proliferation (30). Adhesion molecules are 
one of the candidates for cardiovascular imaging as described 
later in this review, and innovative cardiovascular imaging using 
“active-targeting” strategy is being investigated. Regardless of 
the benefits of “active targeting,” only a few clinically validated 
nanomaterials utilize this strategy. Engineered protein combining 
IL-2 and diphtheria toxin (Ontak®) is the only FDA-approved 
“active-targeting” nanomaterial to date (15).
THe ROLe OF MONOCYTeS/
MACROPHAGeS iN CORONARY ARTeRY 
DiSeASe
Monocytes/macrophages play a key role in the inflammatory 
hypothesis of atherothrombosis (31). Atherogenesis starts with 
endothelial dysfunction caused by oxidative, hemodynamic, 
or biochemical stimuli (from smoking, hypertension, or 
5Katsuki et al. Nanomedicine for Cardiovascular Disease
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dyslipidemia) and inflammatory factors. Endothelial dysfunc-
tion leads to enhanced permeability for cholesterol-containing 
low-density lipoprotein (LDL) particles and the expression of 
adhesion molecules to promote adhesion of circulating mono-
cytes. Adhesive monocytes migrate into subendothelial space by 
chemoattractant proteins including monocyte chemoattractant 
protein-1 (MCP-1), where monocytes are differentiated into 
macrophages by macrophage-colony stimulating factor and 
activated through phagocytosis of oxidized lipid components to 
become foam cells. Activated macrophages secrete inflammatory 
cytokines to trigger positive feedback loop between cytokines and 
immune cells and matrix metalloproteinases (MMPs) leading to 
fibrous cap thinning. Rupture-prone plaques are characterized 
by the abundant accumulation of innate immune cells (mainly 
monocytes/macrophages), lipid core formation, and induction of 
several proteinases that catabolize the extracellular matrix (32).
Monocytes are functionally heterogeneous and are classified 
into at least two major subsets in mice: inflammatory monocytes 
(Ly-6ChighCCR2+CX3CR1low) and non-inflammatory monocytes 
(Ly-6ClowCCR2−CX3CR1high) (33). Previously, we developed a 
mouse model of “plaque rupture” utilizing a high-fat diet and 
angiotensin II infusion in apolipoprotein E (ApoE)-deficient 
mice and reported that adoptive transfer of Ly-6ChighCCR2+ 
inflammatory monocytes increases buried fibrous caps in the 
brachiocephalic arteries (34), suggesting a critical role for 
inflammatory monocytes in plaque destabilization. Although 
their functional similarities have not been fully determined, 
CD14++CD16− classical monocytes and CD14+CD16++ non-
classical monocytes are described as their respective counter-
parts of Ly-6Chigh and Ly-6Clow monocytes according to their 
chemokine receptor expression in humans, and intermediate 
monocytes (CD14++CD16+) have been recently identified as not 
only a transitory state but also likely to possess unique features 
(35). There were not any significant differences in the peak levels 
of circulating CD14++CD16− monocytes among the patients with 
AMI, unstable angina pectoris (UAP), and stable angina pectoris 
(SAP), but that of circulating CD14+CD16+ monocytes (defined 
as CD14++CD16+ plus CD14+CD16++ monocytes) were signifi-
cantly decreased in AMI patients compared with those in patients 
with UAP or SAP (36). A conventional paradigm proposed two 
subpopulations in macrophages corresponding to the monocyte 
heterogeneity: “classically activated or inflammatory M1 mac-
rophages” and “alternatively activated or anti-inflammatory M2 
macrophages.” Although the balance between “M1” and “M2” 
subpopulations may contribute to the development of cardio-
vascular disease, emerging evidence suggests that heterogeneity 
of macrophage subpopulation seems much more complex than 
“M1” and “M2” dichotomy (37). “M2” macrophages are divided 
into at least three subpopulations according to the stimulus they 
are activated; “M2a,” “M2b,” and “M2c.” All “M2” macrophages 
have anti-inflammatory properties to secrete IL-10 and TGF-β. 
“M2b” is an exception because they additionally secrete pro-
inflammatory cytokines, such as IL-1β, IL-6, and TNFα. The 
tissue microenvironment in atherosclerotic plaques can affect 
macrophage population (38). Oxidized phospholipids induce 
“Mox” and intraplaque hemorrhage induces “Mhem (HA-mac)” 
or “M(Hb).” Although localization of “Mox” in human 
atherosclerotic lesions remains to be elucidated, the population 
was detected in approximately 30% of macrophages in advanced 
atherosclerotic plaque of LDL receptor-deficient mice. “Mox” 
not only shows an pro-inflammatory phenotype by producing 
cyclooxygenase-2 and IL-1β but also control redox status by 
inducing redox-regulating genes such as heme oxygenase-1 (HO-
1), sufiredoxin-1 (Srnx1), and thioredoxin reductase 1 via nuclear 
factor erythroid 2-like 2 (NFE2L2). They also display reduced 
chemotactic and phagocytic capacities, which might contribute 
to perpetuation of inflammation and tissue damage (39). “Mhem” 
(previously named as “HA-mac” by the same investigators), origi-
nally defined as CD163high human leukocyte antigen-DRlow, was 
detected in human hemorrhaged atherosclerotic plaque. “Mhem” 
is an atheroprotective subpopu lation that drives adaptation to 
intraplaque hemorrhage through activation transcription factor 
1-mediated induction of HO-1 by heme (40). Another investiga-
tors named this population “M(Hb)” and further demonstrated 
that “M(Hb)” has high expression of “M2 markers” mannose 
receptor and CD163, and reduces ROS production and promotes 
LXRα-mediated reverse cholesterol transport (41). Platelet 
chemokine CXCL4 induces “M4” macrophages. They lack CD163 
and are unable to increase HO-1 production in response to hemo-
globin or hemoglobin–haptoglobin complexes. Co-expression of 
MMP7 and S100 calcium-binding protein A8 (S100A8) in “M4” 
in human atherosclerotic plaques might lead to plaque desta-
bilization by increased expression of MMP7 and affect lesion 
progression through decreased macrophage proliferation (42). 
In this way, the description of macrophage activation has been 
expanded and confusing, and then a group of scientists proposed 
the updated nomenclature to define the activator, i.e., M(IFNγ), 
M(LPS), M(IL-4), and M(IL-10), instead of the current complex 
nomenclature in in vitro experiments. This helps researchers to 
avoid using different definitions of activated macrophages. They 
also provide the framework within which researchers place a 
given population for in vivo experiments (37).
Macrophage is also a protagonist in myocardial ischemia-
reperfusion (IR) injury and wound healing process of ischemic 
heart disease following AMI. In patients with ST-segment eleva-
tion acute MI (STEMI), early reperfusion is a standard therapy 
to salvage viable myocardium and limit MI size. Regardless of 
significant reductions in door-to-balloon time in the last decade, 
the mortality of patients with MI has not improved as shown in 
recent cohort studies. It is well recognized that the reperfusion of 
coronary arteries can paradoxically induce cardiomyocyte death, 
called “myocardial IR injury.” The major contributing factors 
in myocardial IR include ROS, calcium overload, and the rapid 
restoration of physiological PH at reperfusion, which induces the 
opening of the mitochondrial permeability transition pore that 
leads to the necrosis and apoptosis of cardiomyocytes in the first 
several minutes of reperfusion. Over several hours after reperfu-
sion, myocardial inflammation contributes to cardiomyocyte 
apoptosis and the healing of infarcted myocardium (43, 44). The 
recruitment of neutrophils and inflammatory monocytes is an 
established phenomenon after myocardial injury. Uncontrolled 
macrophage infiltration following MI results in ischemic heart 
failure. We and another group demonstrated that infarcted 
myocardium sequentially recruits Ly-6Chi monocytes and Ly-6Clo 
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monocytes in murine MI model (45) and IR injury model (46); 
Ly-6Chi monocyte dominates in early phase to exhibit inflam-
matory functions including phagocytic and proteolytic activity, 
while Ly-6Clow monocyte dominates in later phase to resolute 
inflammation and promote angiogenesis. In consistent with this 
preclinical data, circulating CD14++CD16− and CD14+CD16+ 
monocytes sequentially increase in patients with AMI. The peak 
levels of circulating CD14++CD16− monocytes were negatively 
correlated with the degree of myocardial salvage, suggesting 
that manipulating classical inflammatory monocyte could be a 
therapeutic target for salvaging for ischemic myocardial damage 
after MI (36).
Monocyte chemoattractant protein-1 belongs to the CC 
chemokine subfamily and its primary receptor CCR2 is highly 
expressed on a subpopulation of monocytes (Ly-6Chigh mono-
cytes in mice and CD14++CD16− monocytes in humans). These 
inflammatory monocytes depend on CCR2 to migrate into the 
injured tissue. We previously demonstrated that systemic gene 
therapy with plasmids encoding 7ND, a deletion mutant of 
MCP-1, limits atherogenesis associated with increased lesional 
extracellular matrix content, one of characteristics of stable 
plaques, without any effects on serum lipid concentration (47). 
Furthermore, this gene therapy not only limits progression of 
established preexisting atheroma but also leads to plaque sta-
bilization (48). We then utilized the 7ND-incorporated PLGA 
nanoparticle for interfering with MCP-1/CCR2 signaling and 
demonstrated inhibition of macrophage accumulation in the 
atherosclerotic plaque, followed by amelioration of morpho-
logical characteristics similar to human destabilized/ruptured 
plaque in the brachiocephalic artery of ApoE-deficient mice 
(34). Leuschner et al. demonstrated that inhibition of monocyte 
CCR2 with siCCR2-incorporated lipid nanoparticle inhibits 
macrophage accumulation in sites of inflammation and reduces 
atherosclerotic formation and infarct size in myocardial IR injury 
(49). Another group reported that blockade of CCR2 markedly 
reduced macrophage infiltration in ischemic lesions that results 
in attenuation of myocardial IR injury in mice via inhibition 
of macrophage-related oxidative stress and MMPs (50) They 
also demonstrated that macrophage infiltration into infarcted 
tissue was impaired in CCR2−/− mice after coronary ligation 
and the CCR2 deficiency ameliorates post-MI left ventricular 
(LV) remodeling via inhibition of macrophage-related MMPs 
(51). These data suggested that inflammatory subpopulations 
of monocytes/macrophages are feasible therapeutic targets for 
coronary artery disease.
Other immune cells, including dendritic cells (DCs), 
T cells, and B cells, also play important roles in atherosclerosis. 
A predominant subpopulation of T  cells in atherosclerotic 
lesion is CD4+ T cells. CD8+ T cells and natural killer T cells 
are minor T cell subpopulations. Antigen-presenting cells such 
as macrophages and DCs process the disease-related antigens 
including oxidized LDL, heat-shock proteins and microbes, and 
present them to CD4+ T cells as fragments loaded onto major-
histocompatibility-complex class II molecules, which translates 
innate to adaptive immunity and is one of the therapeutic 
targets in adaptive immunity. In fact, vaccination targeting oxi-
dized LDL-immuned DCs ameliorates atherosclerosis in LDL 
receptor-deficient mice (52). Activated T  cells subsequently 
produce the type 1 helper T (Th1) cytokines (e.g., interferon γ) 
to initiate pro-inflammatory responses. Atherosclerotic lesions 
usually contain Th1 cytokines rather than the type 2 helper 
T (Th2) cytokines. In contrast, regulatory T  cells modulate 
the process by producing anti-inflammatory cytokines, such 
as IL-10 and transforming growth factor-β (TGF-β) (53). The 
role of B cells in the progression of atherosclerosis still remains 
poorly understood, but it has recently gained more attention. 
B  cells have two main subsets in mice based on their origin; 
B1 and B2. The role of the majority subset B2 cells in ath-
erosclerotic lesion is controversial, while B1 cells seem to be 
atheroprotective (54). The corresponding B  cell subsets in 
humans have not been clearly demonstrated. Nanomedicine 
can be applied to those atherosclerosis-regulating immune cells. 
However, the application of nanomedicine to atherosclerotic 
disease is extremely limited so far. A previous study demon-
strated that intranasal immunization with chitosan/pCETP 
nanoparticles inhibits atherosclerosis in rabbit, in which the 
nanoparticulation enabled an efficient delivery of the antigen 
peptide to antigen presenting cells while sparing mucociliary 
clearance (55). Further studies are needed for the development 
of nanomedicine targeting adaptive immunity by utilizing 
nanoparticles as antigen delivery carriers of vaccination.
NANOMATeRiALS FOR iMAGiNG  
OF MACROPHAGeS
We have described that macrophage-mediated inflammation 
plays a crucial role in coronary artery disease. Hence, imaging 
of macrophages provides insight for future therapeutic options 
for cardiovascular diseases, in which several nanomaterials 
are being investigated as new imaging modalities. Developing 
those modalities for imaging macrophages is also indispensable 
in terms of quantitative analysis of therapeutic effects of anti-
inflammatory drugs. Computed tomography (CT) is widely used 
for imaging of coronary artery in clinical setting. Nanomaterials 
for CT are limited because it requires high concentrations of 
absorbent nanomaterials to detect macrophages with X-ray. 
N1177, a crystalline iodined aroyloxy ester covered with a 
polymer, can detect macrophage-rich arterial walls in rabbits 
by CT (56). Macrophage-targeted gold high-density lipoprotein 
(HDL) nanoparticle can be localized in the macrophages of 
atherosclerotic plaque in the aorta of ApoE-deficient mice (57). 
MRI has high soft tissue contrast resolution and can detect 
plaque morphology non-invasively without radiation exposure. 
SPIO nanoparticle and ultrasmall superparamagnetic iron oxide 
(USPIO) are nanomaterial developed as the negative contrast for 
MRI. SPIO- and USPIO-based contrast agents consist of iron 
oxide core with hydrophilic polymeric coating, such as dextran-
coated monocrystalline iron oxide nanoparticle-47 (MION-47) 
and dextran-crosslinked iron oxides. High-resolution MRI after 
administration of MION-47 can assess macrophage burden in 
atheromata induced by balloon injury of cholesterol-fed New 
Zealand White rabbits (58). In clinical setting, ATHEROMA trial 
has been conducted to examine USPIO-related signal change in 
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patients with carotid stenosis >40%, but USPIO-enhanced MRI 
did not predict cardiovascular events significantly (59). On the 
other hand, USPIO-based contrast, ferumoxytol, has succeeded 
in characterizing infarcted myocardium mainly by detecting 
infiltrating macrophages (60). There are some reagents that adopt 
“active-targeting” strategy to image lesional macrophages. One 
good example is that iron oxide nanoparticle conjugated with 
ligand of vascular cell adhesion molecule 1 (VCAM-1) visual-
ized VCAM-1-expressing endothelial cells and macrophages in 
ApoE-deficient mice (61). Nano-sized probes for near infrared 
fluorescence (NIRF) are used in animal studies. The excitation 
and emission wavelengths of NIRF probes range from 600 to 
900  nm. In that range, the absorbance and scattering of bio-
logical tissues are relatively low. These probes are designed to be 
activated when target protease cleaves protease-specific peptide 
substrates linked to quenched fluorescent dyes. MMP (62, 63) 
and cathepsin are used as the substrates to image macrophage 
burden (64).
ANTi-iNFLAMMATORY THeRAPeUTiCS 
wiTH NANOMATeRiALS FOR CORONARY 
ARTeRY DiSeASe
Atherosclerosis
We have recently developed an innovative nano-DDS utiliz-
ing polymeric PLGA nanoparticle-incorporating pitavastatin 
(Pitava-NP) without PEGylation to enhance the anti-inflammatory 
effects of statin on monocyte/macrophage-mediated inflam-
mation of coronary artery disease. The average diameter of 
polymeric nanoparticles is 200 nm. Fluorescence-labeled nano-
particle (FITC-NP) was incorporated mainly Lineage (CD90/
B220/CD49b/NK1.1/Ly-6G)−CD11b+ monocytes in blood and 
Lineage−CD11b+ monocytes/macrophages in aorta by intrave-
nous injection (Figure  2A). Fluorescence microscopic images 
demonstrated that FITC signal was observed in atherosclerotic 
plaque of brachiocephalic artery 24 h after intravenous injection 
of FITC-NP, suggesting that FITC-NP was passively delivered to 
atherosclerotic lesion with enhanced permeability (Figure 2B). 
Time course analysis of FITC signal in peripheral and aortic leu-
kocytes by flow cytometry revealed that the delivery of FITC-NP 
to peripheral monocytes was followed by its delivery to aortic 
macrophages over 2–7  days after injection, suggesting a direct 
delivery of intravenous PLGA nanoparticles to blood monocytes, 
which gradually migrate to the atherosclerotic aorta. Weekly 
intravenous treatment with Pitava-NPs reduced circulating 
inflammatory Ly-6Chigh monocytes, macrophage accumulation in 
the atherosclerotic lesions of the aortic root, and ameliorated 
morphological characteristics similar to human destabilized/
ruptured plaque in the brachiocephalic arteries of ApoE-deficient 
mice (Figures 2C,D) (34). In consistent with these data, a preclini-
cal study from other investigators reported that a statin-loaded 
reconstituted HDL (rHDL) nanoparticle inhibits atherosclerotic 
formation. Using dual gadolinium and fluorescent dye-labeled 
rHDL nanoparticle, they demonstrated that intravenously 
administered rHDL was incorporated into lesional monocytes 
and macrophages, and inhibits plaque formation with reduced 
macrophage content in the aortic root (65).
Myocardial iR injury
Several pharmacological agents, including statins and erythro-
poietin analogs, have been shown to reduce MI size in preclinical 
studies (44). However, several clinical trials on pharmacological 
cardioprotection for myocardial IR injury have failed to dem-
onstrate a positive impact on clinical outcome, and there is no 
effective therapy for preventing myocardial reperfusion injury 
in STEMI patients (44, 67). One possible explanation for the 
failure of current clinical trials is an insufficient drug delivery 
during a limited interventional time window, while administered 
at the time of reperfusion. Therefore, from a clinical perspective, 
it is feasible to apply an effective DDS that facilitates delivery 
to the sites of IR injury during reperfusion, a clinically feasible 
time point. In addition to macrophage-mediated inflammation, 
the activation of pro-survival kinases including PI3K/Akt and 
Erk1/2 that are known as reperfusion injury salvage kinases 
(RISK) in ischemic myocardium is another potential therapeutic 
target to reduce reperfusion-induced necrosis and apoptosis, and 
then limits MI size. Statins are known to afford cardioprotection 
from IR injury in animals (68). The cardioprotection of statins 
on infarct size is mediated partly by activating the RISK pathway. 
Intravenously injected nanoparticles accumulate not only in 
MPS but also in injured tissues, including IR myocardium, where 
vascular permeability is enhanced (13). Thus, nano-DDS may be 
a feasible for myocardial IR injury targeting both inflammatory 
monocytes/macrophages and ischemic myocardium. Therefore, 
we examined the efficacy of Pitava-NP as a DDS for myocardial 
IR injury. In a rat model of myocardial 30-min IR, PLGA nano-
particles were found exclusively in the ischemic myocardium 
(Figure  3A). Flow cytometric analysis showed the incorpora-
tion of FITC-NPs in CD11b+ leukocytes in blood and IR heart. 
Intravenous treatment with Pitava-NPs at the time of myocardial 
reperfusion significantly reduced infarct size 24 h after reperfu-
sion (Figure  3B). The therapeutic effect of Pitava-NP derived 
from the inhibition of MCP-1/CCR2 pathway by inactivation 
of NF-κB, which resulted in reduced macrophage-mediated 
inflammation (Figure 3C) and the activation of RISK pathway 
in ischemic myocardium (69). To establish preclinical proof-
of-concept, we also demonstrated the therapeutic efficiency of 
Pitava-NPs in a preclinical conscious pig IR injury model (70). 
These data suggested that nano-DDS of statin to inflammatory 
cells and ischemic myocardium is a feasible strategy for the 
treatment of myocardial IR injury. Other nanomaterials can 
be applied as a nano-DDS for myocardial IR injury. PEGylated 
liposomes also showed the prolonged circulating time in blood 
and the specific accumulation in ischemic/reperfused myocar-
dium. The liposomes encapsulating adenosine demonstrated the 
enhanced cardioprotection effects of adenosine against myocar-
dial IR injury in rats (71). Dendrimer nanoparticles might be 
another candidate for the nano-DDS due to selective localization 
in ischemic myocardium (72). Further studies are needed to 
assess the therapeutic effects of a dendrimer–drug conjugate in 
myocardial IR injury.
FiGURe 2 | Efficacy of pitavastatin-nanoparticle in atherosclerotic mice. (A) Flow cytometry of circulating leukocytes 2 days after intravenous injection of poly 
lactic-co-glycolic acid nanoparticles encapsulated with FITC (FITC-NP). The histograms demonstrate FITC uptake by monocytes in the blood and the aorta.  
(b) Fluorescent and light micrographs of brachiocephalic arteries 24 h after intravenous injection of saline or FITC-NP. (C) Flow cytometric dot plots and histograms 
of leukocytes from mice injected intravenously with control (empty)-NPs or pitavastatin-NPs (Pitava-NP). (D) Weekly intravenous injection of Pitava-NP increased 
fibrous cap thickness and decreased the number of buried fibrous caps in the atherosclerotic plaques with reduced macrophage accumulation (Mac-3) and 
monocyte chemoattractant protein-1 (MCP-1) expression. Arrows indicate disrupted/buried fibrous caps. We reused these data according to the Copyright Transfer 
Agreement with the publisher (34, 66).
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Post-Mi Lv Remodeling
Recent advances in therapeutic strategy including coronary 
intervention and optimal medication decreased the acute phase 
mortality of MI, but the prevalence of chronic heart failure in MI 
survivors is increasing (73). Intractable heart failure due to LV 
remodeling (dilatation and remodeling) associated with increased 
fibrosis and wall thinning after MI remains a major clinical con-
cern. Therefore, there is also an unmet need for cardioprotective 
modalities to ameliorate post-infarct LV remodeling. The infarcts 
show high inflammatory response with the recruitment of innate 
immune cells including macrophages and monocytes derived 
from extramedullary hematopoiesis such as spleen (74). We have 
examined the efficacy of PLGA nanoparticles as a DDS for post-
infarct LV remodeling. After permanent left anterior descending 
coronary artery (LAD) ligation, Pitava-NP was intravenously 
administered for three consecutive days. Intravenously injected 
FiGURe 3 | Efficacy of pitavastatin-nanoparticle in myocardial ischemia-reperfusion injury. (A) Representative light (upper) and fluorescence (lower) 
stereomicrographs of cross-section of the ischemia-reperfusion (IR) hearts 3 h after intravenous injection of saline, FITC alone, or FITC-NP. (b) Intravenous treatment 
with Pitava-NP at the time of reperfusion reduced infarct size 24 h after reperfusion. (C) Cross-sections from IR myocardium stained with NF-κB, ED-1, and 
monocyte chemoattractant protein-1 (MCP-1). We reused these data according to the Copyright Transfer Agreement with the publisher (69).
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FITC-NPs were delivered to Lineage−CD11b+ monocytes in the 
blood, spleen, and heart, but not in non-infarcted myocardium 
within the area at risk due to coronary ligation (Figure 4A), sug-
gesting that the beneficial effects of Pitava-NPs on post-infarct 
LV remodeling can be predominantly derived from those on 
inflammatory cells. Actually, Pitava-NP decreased macrophage 
accumulation in the heart by inhibiting not only angiotensin 
II-mediated monocyte mobilization from the spleen (Figure 4B) 
but also monocyte mobilization from the bone marrow that is sup-
posed to be mediated by CCR2 (75). Intravenous treatment with 
Pitava-NPs after MI induced by permanent LAD ligation attenu-
ated post-infarct LV remodeling associated with reduced mono-
cyte/macrophage accumulation in the heart (Figure  4C) (76). 
A delayed transition from inflammatory to anti-inflammatory 
macrophages by prolonged recruitment of classical inflammatory 
monocytes to myocardium may also interfere with post-infarct 
LV remodeling (77). Other investigators have intervened a tran-
scription factor that shifts macrophages to inflammatory subsets 
by utilizing siRNA lipid nanoparticles targeting interferon regu-
latory factor 5 (IRF5). They demonstrated that siIRF5 improves 
post-infarct LV remodeling by reprogramming macrophages 
toward anti-inflammatory subsets (78).
SUMMARY AND CLiNiCAL PeRSPeCTive
In this review, we have summarized a series of evidence includ-
ing (1) the anti-inflammatory therapeutics for coronary artery 
disease, (2) a variety of nanomaterials for drug delivery systems, 
(3) the role and imaging of monocytes/macrophages in coronary 
artery disease, and (4) application of nano-DDS based on PLGA 
nanoparticle to coronary artery disease, such as plaque destabi-
lization, IR injury, and post-MI LV remodeling. Applications of 
nano-DDS for coronary artery disease is a feasible strategy by 
utilizing increased incorporation of nanomaterials by MPS and 
enhanced permeability of inflammatory vasculature (Figure 1). 
In addition to the therapeutic effects of nano-DDS on coronary 
artery disease, there are a wide variety of opportunities to 
combine nano-DDS and various therapeutic agents, including 
chemical, nucleotide, peptide, and others, which may extend the 
possibility of current pharmacotherapy for several cardiovascular 
diseases. Possible application of nano-DDS in other cardiovas-
cular diseases may include, pulmonary hypertension (79, 80), 
vein graft disease (81), and coronary artery stents (82). The 
clinical application of nano-DDS utilizing Good Manufacturing 
Practice-compliant Pitava-NPs in this review is in progress. 
We have already completed phase I/IIa investigators’ initi-
ated clinical trial testing the efficacy of Pitava-NP in patients 
with critical limb ischemia in the Kyushu University Hospital 
(UMIN000008011). We have also completed a phase I clinical trial 
testing the safety of an intravenous administration of Pitava-NP 
in healthy volunteers (UMIN000014940). Recently, phase III 
CANTOS trial targeting interleukin-1β with human anti-IL-1β 
monoclonal antibody, canakinumab, has demonstrated that the 
inhibition of systemic inflammation may reduce cardiovascular 
risk even in the absence of concomitant lipid lowering (83). This 
trial has proved the concept that anti-inflammatory therapeutics 
targeting innate immunity pathway can be applicable in humans, 
and our novel DDS utilizing PLGA polymer-based nanotechnol-
ogy might be one of promising therapeutic strategies for various 
cardiovascular diseases in the near future.
FiGURe 4 | Efficacy of pitavastatin-nanoparticle in post-myocardial infarction left ventricular (LV) remodeling. (A) Cross sectional pictures of the infarcted myocardium 
observed under fluorescent microscope 3 days after LAD ligation. Saline or FITC-NP were injected for three consecutive days after ligation. Weak fluorescent signals 
observed in infarcted zones are auto-fluorescence from dead cardiomyocytes. (b) (Upper panel) Splenic sections stained with anti-CD11b antibody (red) and DAPI 
(blue) showing the subcapsular red pulp. (Lower panel) Dot plots of flow cytometric analysis of spleen samples. Treatment with Pitava-NPs inhibited MI-induced 
Lineage (CD90/B220/CD49b/NK1.1/Ly-6G)−CD11b+ monocyte reduction in the spleen. (C) Intravenous treatment with Pitava-NPs for three consecutive days 
ameliorated LV remodeling 4 weeks after myocardial infarction. We reused these data according to the Copyright Transfer Agreement with the publisher (76).
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